Investment Q&A

Q: Assessment for JUNO ? Is it a good entry ? Thank you

Q: Any further developments in Mdx that would warrant buying it or is it still a wait & see situation because of its small size? Thanks as always for your great advice.
Dave

Q: Re: Aug.25/17 comment from Bob on SIS big volume. This is where Technical Analysis/Stock Charts may play a role looking forward & backward combining the fundamentals. The stock has corrected roughly 30% from a high of 17.55 to its current low of 12.04. Simple charting platforms such as Moving Averages-Bollinger Bands-Relative Strength Index-MACD might of helped to find a bottom & choose an entry point.Could you tell us the size of the block trade & the price.
This could tell you where institutions are prepared to take a stand. The stock looks somewhat clean now & may return to its upward momentum. Regards: Ken

Q: Mr. Hodson, this is still about GUD. Considering your recent report, the rating of A- granted, its recent value of $8.31, I hope it goes well, which is not the case currently. Do you still have confidence in it ?

Q: As a new member of 5i Research, I first want to thank you for the service you provide. Fantastic.

I am reviewing the Canadian portion of my RRSP, sector by sector. I have a balanced approach and 15+ years ahead of me before transferring to a RRIF.

I find myself a bit underweight and concentrated in Healthcare, owing only NHW.UN (4% of Canadian portfolio). I was thinking of switching half into CSH.UN for diversification within the Real Estate/Healthcare space, then add a 3% position in GUD for more growth. What are your thoughts?

Note: The US portion of my RRSP, which is half the size of my Canadian portfolio, is invested in Mutual funds with Healthcare/Big Pharma representing about 16% of my US holdings. So my strategy would bring Healthcare to 10% overall in my RRSP.

Thx.

Q: On Nov 26, 2016 I asked if CRH has risen too quickly and was likely to decline materially. You mentioned the fundamentals were strong and it was not like other prominent TSX collapses of recent years.

Now that the stock has collapsed rather predictably I ask why do you still think share price momentum is a good thing to chase.

Q: Phm's earnings were not to bad. Why the drop in stock price?

Thanks

Q: Can I please get your opinion of SIS' newest acquisition.

Thanks

Dave

Q: Hello 5i,
If I am looking at starting a position in SIS when it starts showing positive "price momentum", what are the 3 -5 primary factors that you consider to determine "price momentum" and also could you please quantify the parameters that you prefer (for example, if one of your factors is RSI, do you favour 14 or another value)?

Q: Big volume on SIS today of 666,000 shares. Daily volume is around 30,000 period July 27th to August 10th period. Good sign to me as a holder of SIS is that Investors Purchased 666,000 shares. What are your thoughts as to whom may be buying. RAK.

Q: I am thinking of purchasing Nova Nordisk in my US RRSP account. Please share your thoughts on this company.
Thanks Gord

Q: How come SIS sucks lately? positive quarter and the stock seems to be in free fall! -26% to date!

Q: Good morning,
Could you comment on the big drop in the stock price that is surely related to the Spruce Point Capital report on TOS, and your comments on the report? Thanks.

Q: Please comment on their Q2.

Q: what is your thoughts on the earnings release. you were mostly positive about phm on bnn yesterday.dave

Q: do you know this company, their earnings just announced were very good, would you buy it? it seems like they are getting wins on their silicone adhesives. dave

Q: with my book value of $5000+ for CRH do you think it is worth holding on or just take the loss and go forward. Thank you

Q: Good Morning
Can you comment on this article? Is it strictly motivated on self interest? Thanks

https://seekingalpha.com/article/4099862-prometic-life-sciences-true-underdog

Q: Hi Team,
Following a question about Canadian and US health care sector opportunities, I am trying compare and contrast IBB (iShares Nasdaq Biotechnology ETF) with XBI (SPDR S&P Biotech ETF). I realize the former focuses on large companies and has more concentrated positions in top holdings while the latter focuses on small companies with a more even distribution of holdings. What are your thoughts about a risk/return trade off between the two ETFs and what timeframe would you be considering to hold either one for an investment thesis to pan out? If you had to pick one, which would it be and why?
Many thanks, Michael

Q: For those deeply under water on CRH, still in the stock and looking for positives:

1) Look at the Cash Flow Statement (not the Income Statement):
- This business makes real cash... CF-Operation is $9.75M
- Deducting 'non-controlling interest of $2.2 still leaves $7.5M
- CF Financing noisy due to retirement of high interest Crown and replacing by Scotia 3.5% loan - but there is cash generated for acquisition, debt replayment, etc.


2) Mawer Management is not selling... they are buying (as of end July)!
- Guy wondered about Mawer on July 16. I also track them as they are the best Management firm. Like everyone, they will have their share of losers and this may be one (they are sure deep under water) - so no guarantee but they are buying, not selling:
- Q2 data from Morningstar, they bought 924K shares and owned 6.43%
- How about July when the CMS reimbursement rate occurred? They bought +24% more (they manage the 'BMO enterprise' fund)
- How about after Q2? That we don't know yet...


3) One Director bought shares (independent Director, not Management)
- Per canadianinsider, Tood Patrick bought 50,000 shares on Aug 9/10
- Still would like to see the CEO or other Management buy but this is a first sign.